HC Wainwright reissued their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a research note issued to investors on Friday, MarketBeat.com reports. The brokerage currently has a $130.00 price target on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently issued reports on HALO. Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $95.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Friday, November 6th. Zacks Research lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 11th. Morgan Stanley cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $105.00 to $109.00 in a report on Wednesday, November 11th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Finally, Leerink Partners lowered Halozyme Therapeutics from an “outperform” rating to a “hold” rating and lifted their target price for the stock from $110.00 to $117.00 in a report on Friday, November 6th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $110.17.
Read Our Latest Research Report on Halozyme Therapeutics
Halozyme Therapeutics Stock Down 1.8%
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.09. The business had revenue of $492.97 million for the quarter, compared to analysts’ expectations of $491.63 million. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. The business’s quarterly revenue was up 39.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.72 EPS. Research analysts predict that Halozyme Therapeutics will post 8.34 EPS for the current year.
Insider Transactions at Halozyme Therapeutics
In related news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $75,534,196.40. The trade was a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,000 shares of the stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $96.43, for a total transaction of $482,150.00. Following the completion of the sale, the director directly owned 48,609 shares in the company, valued at approximately $4,687,365.87. The trade was a 9.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 149,226 shares of company stock valued at $15,744,643 in the last 90 days. 2.50% of the stock is currently owned by corporate insiders.
Institutional Trading of Halozyme Therapeutics
A number of large investors have recently modified their holdings of the business. American Century Companies Inc. increased its holdings in shares of Halozyme Therapeutics by 4.8% in the 3rd quarter. American Century Companies Inc. now owns 112,764 shares of the biopharmaceutical company’s stock worth $12,449,000 after buying an additional 5,145 shares during the last quarter. Kestra Advisory Services LLC lifted its holdings in shares of Halozyme Therapeutics by 47.9% during the 3rd quarter. Kestra Advisory Services LLC now owns 14,793 shares of the biopharmaceutical company’s stock worth $1,633,000 after acquiring an additional 4,788 shares during the last quarter. Advisors Asset Management Inc. bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth $776,000. Zacks Investment Management grew its position in Halozyme Therapeutics by 2.6% in the third quarter. Zacks Investment Management now owns 33,464 shares of the biopharmaceutical company’s stock worth $3,694,000 after acquiring an additional 837 shares in the last quarter. Finally, Integrated Wealth Concepts LLC grew its position in Halozyme Therapeutics by 15.2% in the third quarter. Integrated Wealth Concepts LLC now owns 4,643 shares of the biopharmaceutical company’s stock worth $513,000 after acquiring an additional 612 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.
Recent Halozyme Therapeutics Headlines
Investors following HALO have been watching these headlines:
- Positive Sentiment: HC Wainwright reaffirmed its buy rating and set a $130 price target, suggesting substantial upside from the cited share price. HC Wainwright ratings
- Neutral Sentiment: JPMorgan raised its target to $81 from $79 but maintained a neutral rating; the new target is below the cited share price, signaling a more cautious view. JPMorgan ratings
- Negative Sentiment: A German court overturned the preliminary injunction that had blocked Merck from offering its subcutaneous Keytruda product in Germany. Halozyme says it will pursue a permanent patent case, but the ruling removes an immediate barrier to Merck’s launch and adds uncertainty to the dispute’s potential commercial impact. Report on German court ruling
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
See Also
- Five stocks we like better than Halozyme Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
